Press Releases Archives Public Relations Contacts	Font Size:   June 5, 2007   ABILIFY® (aripiprazole) Supplemental New Drug Application for Pediatric Patients with Schizophrenia Accepted for Priority Review by the U.S. Food and Drug Administration   May 23, 2007   Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents with Schizophrenia   May 21, 2007   Six-Week Investigational Study in Adults with Major Depressive Disorder Evaluates the Effectiveness of Adjunctive Aripiprazole Therapy with Antidepressants   March 25, 2007   EVEREST Data on Short- and Long-Term Use of Otsuka’s Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC’s Late Breaking Clinical Trials   January 23, 2007   Otsuka Pharmaceutical Co., Ltd. Announces Establishment of New Organization   November 16, 2006   New Data On Otsuka’s Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting   May 25, 2006   Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia   May 25, 2005   New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia   May 18, 2005   Multiple Studies at DDW Report on Adacolumn® Apheresis Device in Treating Inflammatory Bowel Disease   November 9, 2004   Poster on Investigational Otsuka Product Receives Presidential Poster Award from American College of Gastroenterology   May 18, 2004   Data Presented at Digestive Disease Week on Two Otsuka Products In Development for Inflammatory Bowel Disease   April 15, 2004   Dr. Ralph Harkins Joins Otsuka Maryland Research Institute, Inc. as Vice President, Biometrics   November 10, 2003   Otsuka's Tolvaptan Decreased Fluid Retention in Hospitalized Patients with Worsening Congestive Heart Failure   September 2, 2003   MR. Yoichi Nishinakamura Joins Otsuka Maryland Research Institute, Inc. as Chairman and Chief Executive Officer   July 22, 2003   Otsuka Initiates Phase III Clinical Trials on Compound for Ulcerative Colitis   October 31, 2002   'Control valve' within heart cells could protect body during heart attacks.
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989